|
MTERF expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.44009282066327E-15 |
| Normal-vs-Stage2 |
4.88789999997241E-06 |
| Normal-vs-Stage3 |
1.04238839782056E-12 |
| Normal-vs-Stage4 |
1.78712600273911E-12 |
| Stage1-vs-Stage2 |
4.185400E-01 |
| Stage1-vs-Stage3 |
2.812000E-01 |
| Stage1-vs-Stage4 |
6.321400E-03 |
| Stage2-vs-Stage3 |
1.490780E-01 |
| Stage2-vs-Stage4 |
1.150210E-02 |
| Stage3-vs-Stage4 |
9.566100E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.82400000003913E-06 |
| Normal-vs-Asian |
3.13649999994503E-06 |
| Caucasian-vs-AfricanAmerican |
9.953400E-01 |
| Caucasian-vs-Asian |
1.035360E-01 |
| AfricanAmerican-vs-Asian |
3.320200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.1592063954331E-13 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
6.217400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.25475194071123E-12 |
| Normal-vs-Age(41-60Yrs) |
1.14686038443779E-13 |
| Normal-vs-Age(61-80Yrs) |
5.20383736102303E-12 |
| Normal-vs-Age(81-100Yrs) |
1.405540E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.570000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.752600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.229200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.358200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.253800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.043800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.395700E-02 |
| Classical-VS-Follicular |
3.143800E-01 |
| Classical-VS-Other |
9.704000E-01 |
| Classical-VS-Normal |
1.62914126633495E-12 |
| Tall-VS-Follicular |
3.309500E-02 |
| Tall-VS-Other |
3.664200E-01 |
| Tall-VS-Normal |
9.40880040545267E-10 |
| Follicular-VS-Other |
7.393800E-01 |
| Follicular-VS-Normal |
3.47430000324778E-08 |
| Other-VS-Normal |
5.899300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.36921593455008E-13 |
| Normal-vs-N1 |
6.69419963905682E-10 |
| N0-vs-N1 |
3.421600E-01 |
|
|
